Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Momentum UCITS ETF 14.09.2026 FTMO.LN IE000CY30YV9 3,150,002.00 USD  96,124,217.40   30.516  ...

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf, President and CEO of Stuart Therapeutics, will participate in a fireside chat discussion at the Citizens Private Ophthalmology Summit on Thursday, September 17, 2026, at 2 p.m. EDT. The Summit will showcase innovation in ophthalmology with prese...

دبي، الإمارات العربية المتحدة--(BUSINESS WIRE)--أعلنت MEX Exchange، منصة التداول الإلكتروني المؤسسي التابعة لمجموعة MultiBank Group، تعيين Brian Liedberg في منصب الرئيس التنفيذي لقسم الإيرادات والرئيس العالمي لقسم المبيعات، ما يعزز قيادتها التجارية بالتزامن مع مواصلة الشركة مسيرة تطوير أعمال التداول المؤسسي وتوسيع حضورها في الأسواق الدولية.يتناول هذا البيان الصحفي الوسائط المتعددة. يمكنك الاطلاع على البيان كاملاً هنا: https://www.businesswire.com/news/home/20260913494703/ar/ينضم Brian Liedberg إ...

DUBAI, Verenigde Arabische Emiraten--(BUSINESS WIRE)--MEX Exchange, het institutionele elektronische handelsplatform van MultiBank Group, maakt de benoeming bekend van Brian Liedberg tot Chief Revenue Officer en Global Head of Sales om het commerciële bestuursteam te versterken nu het bedrijf zijn institutionele handelsactiviteit verder blijft uitbouwen en zijn aanwezigheid op de internationale markten uitbreidt. Liedberg staat garant voor meer dan 30 jaar ervaring in wereldwijde kapitaalmarkte...

CHICAGO--(BUSINESS WIRE)--Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investing insights, today launched Game On, a U.S. brand campaign about a complex challenge facing investors: public and private markets are blurring, putting a premium on clarity across both. Private companies are taking longer to go public, with the median age increasing nearly 60% since 2014, private credit is moving into the mainstream, and semiliquid funds are growing strategies for more investors...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - April 14.09.2026 FAPR.LN IE000WX2HZQ7  200,002.00 USD   5,229,202.16   26.146  ...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

NEW HARTFORD, N.Y.--(BUSINESS WIRE)--PAR Technology Corporation (NYSE: PAR), a leading technology provider powering multi-unit operators across restaurant, retail, and large-scale commerce, today announced that Kwik Fill has selected PAR Retail™ as a strategic technology partner. The long-term partnership will help Kwik Fill deliver more relevant, personalized customer experiences while building a stronger foundation for future growth and innovation. Through the partnership, Kwik Fill will leve...

CRANBERRY TOWNSHIP, Pa.--(BUSINESS WIRE)--Westinghouse Electric Company has successfully completed zero-power high-temperature criticality testing for its eVinci™ microreactor, a defining milestone in the program’s build-test-learn development journey. The work was completed in partnership with Los Alamos National Laboratory and the Nevada National Security Site (NNSS) at the National Criticality Experiments Research Center (NCERC), a National Nuclear Security Administration (NNSA) capability i...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (APOC...